Dietary sulforaphane, a histone deacetylase inhibitor for cancer prevention

Journal of Nutrition

Volumn 139, Issue 12, 2009, Pages 2393-2396

  Ho, Emily ^a,b   Clarke, John D ^a,b   Dashwood, Roderick H ^a,b  

^a OREGON STATE UNIVERSITY   (United States)

^b OREGON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYRIC ACID; DEPSIPEPTIDE; GLUTATHIONE; HEME OXYGENASE 1; HISTONE; HISTONE DEACETYLASE INHIBITOR; NQO 1 PROTEIN; PLANT MEDICINAL PRODUCT; PROTEIN; PROTEIN BAX; PROTEIN P21; SULFORAPHANE; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ACETYLATION; APOPTOSIS; BROCCOLI; BRUSSELS SPROUT; CABBAGE; CANCER CELL; CANCER GROWTH; CANCER PATIENT; CANCER PREVENTION; CANCER SURVIVAL; CAULIFLOWER; CELL CYCLE ARREST; CELL PROLIFERATION; CHEMOPROPHYLAXIS; COLORECTAL CANCER; CONFERENCE PAPER; DIET; DRUG BIOAVAILABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; EPIGENETICS; GENE CONTROL; GENE OVEREXPRESSION; GENE REPRESSION; HIGH RISK PATIENT; HUMAN; MOLECULAR MODEL; PROSTATE CANCER; UPREGULATION; VEGETABLE;

ACETYLATION; ANIMALS; ANTICARCINOGENIC AGENTS; BIOLOGICAL AVAILABILITY; BRASSICA; DIET; DIETARY SUPPLEMENTS; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; GENOMIC INSTABILITY; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; JEJUNUM; MALE; PROSTATIC NEOPLASMS; RATS; THIOCYANATES; TRANSCRIPTION, GENETIC;

EID: 72249122960     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.3945/jn.109.113332     Document Type: Conference Paper

References (28)

1. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, Akiyama M, Chauhan D, Munshi N, et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA. 2004;101:540-545 (Pubitemid 38084672)
2. Brinkmann H, Dahler AL, Popa C, Serewko MM, Parsons PG, Gabrielli BG, Burgess AJ, Saunders NA. Histone hyperacetylation induced by histone deacetylase inhibitors is not sufficient to cause growth inhibition in human dermal fibroblasts. J Biol Chem. 2001;276:22491-22499 (Pubitemid 37410926)
3. Patra SK, Patra A, Dahiya R. Histone deacetylase and DNA methyltransferase in human prostate cancer. Biochem Biophys Res Commun. 2001;287:705-713 (Pubitemid 32912772)
4. Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate. 2004;59:177-189 (Pubitemid 38481229)
5. Halkidou K, Cook S, Leung HY, Neal DE, Robson CN. Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate. Eur Urol. 2004;45:382-389, author reply 9. (Pubitemid 38221414)
6. Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, Kurdistani SK. Global histone modification patterns predict risk of prostate cancer recurrence. Nature. 2005;435:1262-1266 (Pubitemid 40943093)
7. Fronsdal K, Saatcioglu F. Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells. Prostate. 2005;62:299-306. (Pubitemid 40129069)
8. Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA, Richon VM. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 2000;60:5165-5170 (Pubitemid 30739775)
9. Fahey JW, Zhang Y, Talalay P. Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. Proc Natl Acad Sci USA. 1997;94:10367-10372 (Pubitemid 27407048)
10. Chung FL, Conaway CC, Rao CV, Reddy BS. Chemoprevention of colonic aberrant crypt foci in Fischer rats by sulforaphane and phenethyl isothiocyanate. Carcinogenesis. 2000;21:2287-2291
11. Zhang Y, Kensler TW, Cho CG, Posner GH, Talalay P. Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornyl isothiocyanates. Proc Natl Acad Sci USA. 1994;91:3147-3150 (Pubitemid 24130192)
12. Singh AV, Xiao D, Lew KL, Dhir R, Singh SV. Sulforaphane induces caspase-mediated apoptosis in cultured PC-3 human prostate cancer cells and retards growth of PC-3 xenografts in vivo. Carcinogenesis. 2004;25:83-90. (Pubitemid 38128621)
13. Furumai R, Komatsu Y, Nishino N, Khochbin S, Yoshida M, Horinouchi S. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc Natl Acad Sci USA. 2001;98:87-92. (Pubitemid 32095868)
14. Kassahun K, Davis M, Hu P, Martin B, Baillie T. Biotransformation of the naturally occurring isothiocyanate sulforaphane in the rat: identification of phase I metabolites and glutathione conjugates. Chem Res Toxicol. 1997;10:1228-1233 (Pubitemid 27524827)
15. Myzak MC, Karplus PA, Chung F-L, Dashwood RH. A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase. Cancer Res. 2004;64:5767-5774 (Pubitemid 39095576)
16. Myzak MC, Hardin K, Wang R, Dashwood RH, Ho E. Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells. Carcinogenesis. 2006;27:811-819
17. Pledgie-Tracy A, Sobolewski MD, Davidson NE. Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines. Mol Cancer Ther. 2007;6:1013-1021 (Pubitemid 46554571)
18. Dashwood RH, Ho E. Dietary histone deacetylase inhibitors: From cells to mice to man. Semin Cancer Biol. 2007;17:363-369 (Pubitemid 47369168)
19. Myzak MC, Tong P, Dashwood WM, Dashwood RH, Ho E. Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects. Exp Biol Med. 2007;232:227-234 (Pubitemid 46203291)
20. Myzak MC, Dashwood WM, Orner GA, Ho E, Dashwood RH. Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apc-minus mice. FASEB J. 2006;20:506-508 (Pubitemid 46671231)
21. Petri N, Tannergren C, Holst B, Mellon FA, Bao Y, Plumb GW, Bacon J, O'Leary KA, Kroon PA, et al. Absorption/metabolism of sulforaphane and quercetin, and regulation of phase II enzymes, in human jejunum in vivo. Drug Metab Dispos. 2003;31:805-813 (Pubitemid 36617672)
22. Hu R, Hebbar V, Kim BR, Chen C, Winnik B, Buckley B, Soteropoulos P, Tolias P, Hart RP, Kong AN. In vivo pharmacokinetics and regulation of gene expression profiles by isothiocyanate sulforaphane in the rat. J Pharmacol Exp Ther. 2004;310:263-271
23. Ye L, Dinkova-Kostova AT, Wade KL, Zhang Y, Shapiro TA, Talalay P. Quantitative determination of dithiocarbamates in human plasma, serum, erythrocytes and urine: pharmacokinetics of broccoli sprout isothiocyanates in humans. Clin Chim Acta. 2002;316:43-53. (Pubitemid 34028187)
24. Cornblatt BS, Ye L, Dinkova-Kostova AT, Erb M, Fahey JW, Singh NK, Chen M-SA, Stierer T, Garrett-Mayer E, et al. Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast. Carcinogenesis. 2007;28:1485-1490 (Pubitemid 47241798)
25. Ho E, Zempleni J. Overview to symposium "Nutrients and Epigenetic Regulation of Gene Expression.". J Nutr. 2009;139:2387-2388
26. Zempleni J, Chew YC, Bao B, Pestinger V, Wijeratne SSK. Repression of transposable elements by histone biotinylation. J Nutr. 2009;139:2389-2392
27. Kirkland JB. Niacin status impacts chromatin structure. J Nutr. 2009;139:2397-2401
28. Stover PJ. One-carbon metabolism-genome interactions in folateassociated pathologies. J Nutr. 2009;139:2402-2405